FDAsafety guidance83% confidence
HealthPartners Neuroscience Center Research and Innovation - 725333 - 05/19/2026
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (hypophosphatasia) as Efzimfotase alfa shows positive Phase III results in hypophosphatasia.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Rare Diseases · Hypophosphatasia
- Sub-indication
- Hypophosphatasia
Related signal: Efzimfotase alfa shows positive Phase III results in hypophosphatasia